Neuregulin Formulation pH Buffering for Heart Failure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug therapies for heart failure, such as ACE inhibitors, have limited efficacy in reducing mortality and are associated with side effects, while alternative treatments like heart transplantation and mechanical devices are invasive, expensive, and limited by availability.
Innovation Solution
A pharmaceutical formulation of neuregulin (NRG) comprising a NRG polypeptide, a buffering agent to maintain a pH between 3-7, and optional stabilizing agents and salts, which enhances the stability and effectiveness of NRG for treating heart failure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ACE inhibitors are used to treat heart failure, then blood pressure is reduced and heart workload is decreased, but mortality reduction is limited (only 3%-4%) and side effects occur
Solution Approach 1:
The patent changes the therapeutic parameter from conventional ACE inhibition to neuregulin-based ErbB receptor activation. This fundamental parameter change in the treatment mechanism enables improved mortality reduction while avoiding the side effects associated with ACE inhibitors, such as cough, angioedema, and hyperkalemia.
2Reliability
If heart transplantation is performed, then heart failure is effectively treated, but the procedure is invasive, expensive, and limited by donor availability
Solution Approach 1:
The patent replaces the mechanical surgical intervention of heart transplantation with a biochemical therapy using neuregulin peptides. This substitution eliminates the need for invasive surgery, donor organ dependency, and complex immunosuppression protocols, while providing effective treatment through pharmacological activation of cardiac repair mechanisms.
3Reliability
If mechanical devices like biventricular pacemakers are used, then heart failure is treated, but the devices are invasive and expensive
Solution Approach 1:
The patent replaces mechanical device therapy (biventricular pacemakers) with a biochemical approach using neuregulin administration. This substitution eliminates device implantation, lead placement, battery replacement, and associated risks while achieving therapeutic goals through natural biological mechanisms of cardiac cell survival and regeneration.
4Reliability
If neuregulin is administered for heart failure treatment, then myocardial performance is improved, but formulation stability must be maintained
Solution Approach 1:
The patent introduces formulation excipients and buffering agents as intermediaries to stabilize the neuregulin peptide. These auxiliary substances protect the active ingredient from degradation, maintain appropriate pH levels, and ensure formulation stability during storage and administration, thereby enabling the therapeutic benefits of neuregulin to be realized.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves significant stability and effectiveness of NRG, improving myocardial performance and providing a promising therapeutic option for heart failure with reduced side effects.
Implementation Method 1
a buffering agent to maintain a pH between 3-7
Data Source
AI summary
The present invention provides a pharmaceutical preparation for treating a cardiovascular disease. Particularly, the present invention provides a formula of a neuregulin pharmaceutical preparation. The formula consist of neuregulin polypeptide, a buffer, a stabilizer, an excipient, a salt, and another component, can ensure the long-term stability of the neuregulin polypeptide, and can be used for treating a heart failure patient or a patient in a risk of the heart failure.